Real-world usage and effectiveness of recombinant factor IX Fc in haemophilia B from the B-SURE study in France
Therapeutic Advances in Hematology · 2025-07 · 16
DOI: 10.1177/20406207241311535 ↗Kurz gefasst
Fachartikel in der Zeitschrift Therapeutic Advances in Hematology, online erschienen am 26.01.2025. Verfasst von Hervé Chambost und 11 weiteren Autor:innen. Beteiligte Einrichtung: AP-HM, Department of Paediatric Haematology, Immunology and Oncology, La Timone Children's Hospital and Aix Marseille University, C2VN, Marseille, Fr…. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Sobi.
Abstract (Originalsprache)
Background
More real-world data are needed to complement existing phase III studies on the efficacy and safety of recombinant factor IX Fc fusion protein (rFIXFc) in people with haemophilia B.
Objectives
We report final data from the B-SURE study, evaluating the real-world usage and effectiveness of rFIXFc in France.
Methods
Previously treated patients (all ages/severities) received on-demand or prophylactic rFIXFc during B-SURE. Annualised bleeding rate (ABR), injection frequency (IF) and factor consumption (FC) were prospectively evaluated for patients on rFIXFc prophylaxis (primary endpoints). Six months of retrospective factor IX (FIX) data were collected for comparison; patients with ⩾3 months of treatment pre- and post-switch to rFIXFc were analysed.
Design
B-SURE was a 24-month, prospective, non-interventional, real-world study across haemophilia treatment centres in France.
Results
Ninety-one male patients enrolled across 21 centres (34%
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- AP-HM, Department of Paediatric Haematology, Immunology and Oncology, La Timone Children's Hospital and Aix Marseille University, C2VN, Marseille, France.
- Haemophilia Treatment Centre, University Hospital of Caen, Caen, France.
- Haemophilia Treatment Centre, University Hospital of Dijon, Dijon, France.
- Haemophilia Treatment Centre, University Hospital of Strasbourg, Strasbourg, France.
- Haemophilia Treatment Centre, University Hospital of Bordeaux, Bordeaux, France.
- Haemophilia Treatment Centre, University Hospital of Reunion, Reunion Island, France.
ORCID-Profile: Hervé Chambost
Förderung
- Sobi
Zitieren
APA
Chambost, H., Repessé, Y., Genre-Volot, F., Desprez, D., Castet, S. M., Vanderbecken, S., Zidi, M., Gandossi, C., Nüesch, E., Palmborg, H., Santagostino, E., & B-SURE Study Group (2025). Real-world usage and effectiveness of recombinant factor IX Fc in haemophilia B from the B-SURE study in France. Therapeutic Advances in Hematology, 16. https://doi.org/10.1177/20406207241311535
Vancouver
Chambost H, Repessé Y, Genre-Volot F, Desprez D, Castet SM, Vanderbecken S, et al. Real-world usage and effectiveness of recombinant factor IX Fc in haemophilia B from the B-SURE study in France. Therapeutic Advances in Hematology. 2025;16. doi:10.1177/20406207241311535
BibTeX
@article{Chambost2025,
author = {Chambost, Hervé and Repessé, Yohann and Genre-Volot, Fabienne and Desprez, Dominique and Castet, Sabine Marie and Vanderbecken, Stéphane and Zidi, Meriem and Gandossi, Corinne and Nüesch, Eveline and Palmborg, Helena and Santagostino, Elena and B-SURE Study Group, B-SURE Study Group},
title = {Real-world usage and effectiveness of recombinant factor IX Fc in haemophilia B from the B-SURE study in France},
journal = {Therapeutic Advances in Hematology},
year = {2025},
volume = {16},
doi = {10.1177/20406207241311535}
}
EUVIMED